The increasing expectation of human life for the healthcare systems has created increasing difficulties. When people get older, they are increasingly susceptible to chronic diseases and the associated burden of multimorbidity and polypharmacology. Accumulating evidence of laboratory animals has shown that aging can be improved by genetic and environmental measures.
With the emphasis on immediate prospects in aging research, biotech has very little dry powder left to deal with the demographic time bomb that healthcare systems are facing. Even if the initiatives now underway are successful in alleviating illness, which is far from definite, it would take ten years for them to move through clinical development and reach the market. In the meanwhile, what can healthcare systems do? The answer is Digital Medicine.
17:30 - Welcoming ceremony 18:00 - Hacking begins 20:00 - Mentors interacting with the teams. Round 1 (updates after the ideation weekend, choosing the strategy)
Saturday, January 29
18:00 - Pitching workshop 19:00 - Experts' round table 20:00 - Mentors interacting with the teams. Round 2 (Business tools and startup feasibility evaluation)
Sunday, January 30
10:00 - Solutions presentations' admission opens 17:00 - Mentors interacting with the teams. Round 3 (final questions and pitch feedback) 17:30 - Final admissions 18:00 - Solutions presentations' admission closes. Presentations' order is announced 18:30 - Final presentations 20:30 - Finalizing judging round 21:00 - Closing ceremony (Awards might be allocated later next week)
Director, Institute for Aging Research at the Albert Einstein College of Medicine, PI: Nathan Shock Center of Excellence in the Biology of Aging PI: Glenn Center for the Biology of Human Aging. Co-Scientific Director of the American Federation for Aging Research Founder and on the Board of CohBar Inc. Chief Medical Advisor for Life Bioscience
Dr. Barzilai is a chaired Professor of Medicine and Genetics and Director of the biggest Center in the world to study the Biology of Aging and the principal investigator of the Einstein Nathan Shock Center and the Glenn center. He was the recipient of an NIH Merit Award aiming to extend the healthy life span in rodents by biological interventions. He also studies families of centenarians that have provided genetic/biological insights on the protection against aging. Several drugs are developed based, in part, on these paradigm-changing studies. He is the author of over 270 peer-reviewed papers and a recipient of numerous prestigious awards, including the recipient of the 2010 Irving S. Wright Award of Distinction in Aging Research and is the 2018 recipient of the IPSEN Longevity award. He is leading the TAME (Targeting/Taming Aging with Metformin) multi central study to prove that concept that multi morbidities of aging can be delayed in humans and change the FDA indications to allow for next generation interventions. Dr. Barzilai is on the board of AFAR, its scientific director and a founding member of the Academy for Lifespan and Health span. He co-founded CohBar and Lifebioscinces. He has been featured in major papers, TV program and documentaries (2 TEDx and TEDMED) and has been consulting or presented the promise for targeting aging at The Singapore Prime Minister Office, Prime Minister office in Israel, several International Banks, The Vatican, Pepsico, Milken Institute, Davos Economical Forum, and featured in The Wall Street Journal, New York Times, The Economist and Wired Magazine. His book Age Later was published in the June of 2020.
Dr. Nathan Price
Dr. Nathan Price is Chief Scientific Officer of Thorne HealthTech (NASDAQ: THRN). Previously he was CEO of Onegevity, an AI health intelligence company that merged with Thorne prior to the IPO in 2021. In 2019, he was named as one of the 10 Emerging Leaders in Health and Medicine by the National Academy of Medicine, and in 2021 he was appointed to the Board on Life Sciences of the National Academies of Sciences, Engineering, and Medicine. He spent much of his earlier career as Professor and Associate Director of the Institute for Systems Biology (now on leave), co-director with biotechnology pioneer Lee Hood of the Hood-Price Lab for Systems Biomedicine, and is Affiliate Faculty at the University of Washington in Bioengineering and Computer Science & Engineering. He is a Camille Dreyfus Teacher-Scholar, received the 2016 Grace A. Goldsmith award for his work pioneering 'scientific wellness', was a co-founder of Arivale, and received a Healthy Longevity Catalyst Award from the National Academy of Medicine in 2020. He has co-authored more than 180 peer-reviewed scientific publications and given over 200 talks and keynotes. He also served as Chair of the NIH Study Section on Modeling and Analysis of Biological Systems (MABS).
Dr. Kevin Perrott
Kevin Perrott is a successful businessman and owner of a large snowmobile and motorcycle dealership in Canada. After becoming a cancer survivor he decided to focus his efforts on the study of age-related disease and obtained a Ph.D. for work studying natural compounds effects on the inflammation produced by senescent cells in the lab of Judith Campisi at the Buck Institute for Research on Aging. He is Treasurer and co-founder of SENS Research Foundation and former Director of the Methuselah Foundation. He also cofounded Oisin Biotechnologies, a for-profit fighting aging through 'reprogramming' biology. After years of working in both the for-profit and non-profit sectors to accelerate the development of interventions in aging, it became clear that a large reason for the delay is lack of involvement of the consumer and he became the Founder and CEO of OpenCures, a for-benefit enterprise that has created a platform that enables collaboration and synergies between customers and the companies who develop health technologies.